Testing NF-κB-based Therapy in Hemiparkinsonian Monkeys

[1]  N. Hattori,et al.  [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[2]  K. Pahan,et al.  Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive, Upregulates Neuroprotective Parkinson Disease Protein DJ-1 in Astrocytes and Neurons , 2011, Journal of Neuroimmune Pharmacology.

[3]  J. Kordower,et al.  Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates , 2011, Nature Reviews Neuroscience.

[4]  K. Pahan,et al.  Prospects of Statins in Parkinson Disease , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[5]  K. Pahan,et al.  Fibrillar Amyloid-β-Activated Human Astroglia Kill Primary Human Neurons via Neutral Sphingomyelinase: Implications for Alzheimer's Disease , 2010, The Journal of Neuroscience.

[6]  H. Gendelman,et al.  Simvastatin Inhibits the Activation of p21ras and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease , 2009, The Journal of Neuroscience.

[7]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[8]  Howard E. Gendelman,et al.  Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[9]  D. Nicholl,et al.  Genetics of Parkinson’s disease and parkinsonism , 2007, Expert review of neurotherapeutics.

[10]  David N. Messina,et al.  Evolutionary and Biomedical Insights from the Rhesus Macaque Genome , 2007, Science.

[11]  R. Bakay,et al.  Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.

[12]  R. N. Saha,et al.  Regulation of inducible nitric oxide synthase gene in glial cells. , 2006, Antioxidants & redox signaling.

[13]  R. N. Saha,et al.  Up-regulation of BDNF in Astrocytes by TNF-α: A Case for the Neuroprotective Role of Cytokine , 2006, Journal of Neuroimmune Pharmacology.

[14]  G. Weissmann,et al.  Science fraud: from patchwork mouse to patchwork data , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  R. N. Saha,et al.  Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. , 2006, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.

[16]  J. Kordower,et al.  Primate models of Parkinson’s disease , 2003, Experimental Neurology.

[17]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[18]  B. Liu,et al.  Novel anti-inflammatory therapy for Parkinson's disease. , 2003, Trends in pharmacological sciences.

[19]  P. Suzdak,et al.  Systemic Administration of the Immunophilin Ligand GPI 1046 in MPTP-Treated Monkeys , 2001, Experimental Neurology.

[20]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[21]  S. Ghosh,et al.  Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex , 2000 .

[22]  J. Dichgans,et al.  Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.

[23]  J. Pober,et al.  Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. , 2000, Science.

[24]  H. Ichinose,et al.  Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[25]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[26]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[27]  T. Nagatsu,et al.  Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. , 1996, Neuroscience letters.

[28]  P. Södersten,et al.  Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease , 1995, Neuroreport.